<DOC>
	<DOCNO>NCT00001020</DOCNO>
	<brief_summary>AMENDED 11/17/93 : To determine whether pattern response MN rgp120 vaccine alter pre-exposure IIIB rgp120 . ORIGINAL DESIGN : To evaluate safety ( clinical immunologic ) rgp120/HIV-1IIIB vaccine ( gp120 vaccine ) immunization healthy HIV-1 seronegative adult subject . To compare immune response 100 mcg gp120 vaccine versus 300 mcg gp120 vaccine . To determine whether gp120 vaccine immunization cause significant immune response define specific parameter ( e.g. , induction neutralize antibody IIIB isolate HIV-1 , gp120 antigen-specific lymphocytic proliferation ) . Recent evidence suggest gp120 HIV-1 protein great potential vaccine HIV-1 infection . The gp120 envelope protein may produce recombinant DNA technology , study show vaccine capable elicit neutralize antibody activity rodent nonhuman primate specie .</brief_summary>
	<brief_title>A Phase I Study Safety Immunogenicity rgp120/HIV-1IIIB Vaccine Healthy Adult Subjects ( NOTE : Study Extended ONLY Subjects Who Have Previously Received rgp120/HIV-1IIIB rgp120/HIV-1MN VEU 006 VEU 006 Rollover Study )</brief_title>
	<detailed_description>Recent evidence suggest gp120 HIV-1 protein great potential vaccine HIV-1 infection . The gp120 envelope protein may produce recombinant DNA technology , study show vaccine capable elicit neutralize antibody activity rodent nonhuman primate specie . AMENDED 11/17/93 : Selected subject VEU 006 VEU 006 Rollover study receive two injection MN rgp120 vaccine , administer 28 day apart begin 10-16 month last injection . Eight additional clinic visit require . Subjects follow least 6 month . ORIGINAL DESIGN : Twenty-eight subject randomize receive 100 300 mcg rgp120/HIV-1IIIB vaccine ( gp120 vaccine ) match placebo . For dose level , 10 subject receive vaccine four subject receive match placebo . Injections give intramuscularly 0 , 4 , 32 week . Each subject receive treatment low dose level must monitor unacceptable toxicity least 2 week follow initial immunization second dose administer treatment high dose level begin . Subjects follow least 12 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV seronegativity . Good general health . No highrisk behavior HIV infection . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Postive PPD ( unless chest xray negative suggestion active old pulmonary tuberculosis ) . Positive VDRL HBsAG . No febrile illness within 1 week study . Concurrent Medication : Excluded : Concomitant corticosteroid know immunosuppressive drug . Other experimental agent . Patients follow prior condition exclude : History clinically significant cardiac , pulmonary , hepatic , renal , neurologic , autoimmune disease . Prior Medication : Excluded : Other immunization within 4 week prior study entry . Identifiable highrisk behavior HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Viral Vaccines</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>